CERO THERAPEUTICS HOLDINGS (CERO) Company Report

CERO THERAPEUTICS HOLDINGS, INC. presented initial clinical experience for its first-in-class CAR-T therapy, CER-1236, at the Transplantation and Cellular Therapy Meetings on February 4, 2026.
The first-in-human trial demonstrated technical and clinical feasibility with no observed on-target toxicity, cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS).
An index patient with inv(3) AML treated with CER-1236 achieved durable platelet recovery and transfusion independence for 72 days.
The clinical study for CER-1236 has been expanded to include transfusion-dependent MDS, high-risk MDS, and myelofibrosis.

3 days ago

CERo Therapeutics Provides Clinical Update on Phase 1 Trial and Announces Expansion

CERO

New Projects/Investments

CERo Therapeutics Holdings, Inc. provided a clinical update on its Phase 1 CertainT-1 trial for CER-1236 in acute myeloid leukemia (AML) on January 7, 2026.
Investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date in the first cohort.
A patient with myelodysplastic syndrome (MDS) that progressed to AML experienced a 61-day platelet transfusion-free interval after CER-1236 treatment, exceeding an 8-week benchmark.
The company has filed an amendment with the FDA to expand the CertainT-1 trial to include advanced MDS and myelofibrosis (MF) as additional cohorts.

Jan 7, 2026, 9:37 PM

CERO Therapeutics Holdings, Inc. enters into new common stock purchase agreement

CERO

CERO Therapeutics Holdings, Inc. (the "Company") entered into a Common Stock Purchase Agreement with Keystone Capital Partners, LLC (the "Investor") on November 26, 2025.
This agreement allows the Company to issue and sell up to an additional $14,591,939 of its common stock to the Investor.
This new agreement continues an equity line program, with the Company having previously sold shares for aggregate proceeds of approximately $4.4 million (February 2024), $3.1 million (November 2024), and $2.90 million (July 2025) under prior agreements.
The total aggregate amount the Company may issue and sell to the Investor under all related purchase agreements is $25,000,000.
The Company acknowledges that the issuance of these securities could cause dilution to existing stockholders.

Dec 2, 2025, 1:30 PM

CERO Therapeutics Holdings, Inc. Announces Nasdaq Delisting

CERO

Delisting/Listing Issues

Convertible Preferred Issuance

The Nasdaq Hearings Panel has denied CERO Therapeutics Holdings, Inc.'s request for continued listing, resulting in the suspension of its common stock from trading on Nasdaq at the open of trading on October 31, 2025.
This determination was based on the company's non-compliance with the minimum stockholders' equity requirement of $2,500,000, retroactively determined as of April 22, 2025.
CERO has submitted a request for review of this decision by the Nasdaq Listing and Hearing Review Council and is pursuing trading its shares on the OTC Markets.
The company intends to continue its clinical trials for CER-1236 and is exploring financing alternatives, as a $4.75 million financing commitment was contingent on continued Nasdaq listing.

Oct 29, 2025, 11:27 PM

CERO Therapeutics Holdings, Inc. Completes Initial Closing for Series E Convertible Preferred Stock Offering

CERO

Convertible Preferred Issuance

Debt Issuance

CERO Therapeutics Holdings, Inc. (CERO) created 10,000 shares of Series E Convertible Preferred Stock with a par value of $0.0001 per share. The Certificate of Designations for these shares became effective on October 14, 2025.
On October 16, 2025, CERO completed the Initial Closing of its Series E Preferred Stock offering, raising approximately $2.25 million in gross proceeds from the issuance of 3,816 shares.
The total aggregate amount to be funded under the Securities Purchase Agreement is $7 million, with $4.75 million remaining to be funded in additional closings.
The Series E Preferred Stock is convertible into common stock, ranks junior to Series A, on parity with Series C and D, and senior to Series B preferred stock. Holders generally have no voting power. The Company can redeem the shares at 125% of the greater of the Conversion Amount or a price based on the Common Stock's Closing Sale Price.

Oct 16, 2025, 8:17 PM

CERO Therapeutics Holdings, Inc. Enters Securities Purchase Agreement for Series E Convertible Preferred Stock

CERO

Convertible Preferred Issuance

CERO Therapeutics Holdings, Inc. filed an 8-K on October 14, 2025, announcing a Securities Purchase Agreement dated the same day with investors.
This agreement involves the issuance of Series E Convertible Preferred Stock.
As of the first closing date, the company will have 14,342 shares of Preferred Stock issued and outstanding, an increase from the current 10,526 shares.
The proceeds from the sale of these securities will be used for general corporate purposes.

Oct 14, 2025, 1:11 PM

CERO Therapeutics Holdings, Inc. Updates Investor Presentation with Clinical Pipeline and Catalysts

CERO

New Projects/Investments

CERO Therapeutics Holdings, Inc. published an updated investor presentation on September 22, 2025, detailing its Chimeric Engulfment Receptor T cells (CER-T) platform.
The company anticipates several clinical catalysts, including the enrollment of the second and third patients in a Phase 1 Acute Myeloid Leukemia (AML) trial in 3Q 2025, the fourth patient in 4Q 2025, and the initiation of a Phase 1 trial in Ovarian and Non-Small Cell Lung Cancer in Q1 2026.
Initial patient data for Ovarian and Non-Small Cell Lung Cancer is expected in 2H 2026.
The CER-T platform has demonstrated robust preclinical tumor-killing capabilities across liquid and solid tumors, with encouraging Phase 1 data in AML showing an immune response.

Sep 22, 2025, 8:10 PM

Get instant answers from SEC filings, earnings calls & more